{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:25:52Z","timestamp":1786998352976,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004286","name":"Santen Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004286","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.xops.2025.100960","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:43:17Z","timestamp":1760074997000},"page":"100960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Low-Concentration Atropine in Slowing Myopia Progression in Children in Japan: The Randomized, Double-Blind Phase II\/III ORANGE Study"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8375-6879","authenticated-orcid":false,"given":"Kyoko","family":"Ohno-Matsui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae","family":"Igarashi-Yokoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukie","family":"Migita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2025.100960_bib1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/1120672121998960","article-title":"Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute","volume":"31","author":"Nemeth","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.xops.2025.100960_bib2","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100960_bib3","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jamaophthalmol.2019.3103","article-title":"Current prevalence of myopia and association of myopia with environmental factors among schoolchildren in Japan","volume":"137","author":"Yotsukura","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2025.100960_bib4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/519276a","article-title":"The myopia boom","volume":"519","author":"Dolgin","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.xops.2025.100960_bib5","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0140-6736(12)60272-4","article-title":"Myopia","volume":"379","author":"Morgan","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2025.100960_bib6","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ophtha.2018.10.029","article-title":"Potential lost productivity resulting from the global burden of myopia: systematic review, meta-analysis, and modeling","volume":"126","author":"Naidoo","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100960_bib7","doi-asserted-by":"crossref","first-page":"M20","DOI":"10.1167\/iovs.18-25957","article-title":"IMI - Defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies","volume":"60","author":"Flitcroft","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100960_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1167\/iovs.61.4.49","article-title":"The complications of myopia: a review and meta-analysis","volume":"61","author":"Haarman","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100960_bib9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/opo.12305","article-title":"Age of onset of myopia predicts risk of high myopia in later childhood in myopic Singapore children","volume":"36","author":"Chua","year":"2016","journal-title":"Ophthalmic Physiol Opt"},{"key":"10.1016\/j.xops.2025.100960_bib10","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1001\/jamaophthalmol.2020.3451","article-title":"Association of age at myopia onset with risk of high myopia in adulthood in a 12-Year Follow-up of a Chinese cohort","volume":"138","author":"Hu","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2025.100960_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1226438","article-title":"Advances in myopia prevention strategies for school-aged children: a comprehensive review","volume":"11","author":"Tariq","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.xops.2025.100960_bib12","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3390\/pharmaceutics14050900","article-title":"The role of atropine in preventing myopia progression: an update","volume":"14","author":"Chierigo","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xops.2025.100960_bib13","article-title":"Interventions for myopia control in children: a living systematic review and network meta-analysis","volume":"2","author":"Lawrenson","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.xops.2025.100960_bib14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/ICL.0000000000000677","article-title":"Biological mechanisms of atropine control of myopia","volume":"46","author":"Upadhyay","year":"2020","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.xops.2025.100960_bib15","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","article-title":"Atropine for the treatment of childhood myopia","volume":"113","author":"Chua","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100960_bib16","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ophtha.2008.10.020","article-title":"Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine","volume":"116","author":"Tong","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100960_bib17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2)","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100960_bib18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-Concentration Atropine for Myopia Progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100960_bib19","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.18240\/ijo.2023.08.20","article-title":"Efficacy and safety of atropine at different concentrations in prevention of myopia progression in Asian children: a systematic review and meta-analysis of randomized clinical trials","volume":"16","author":"Wei","year":"2023","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.xops.2025.100960_bib20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ajo.2013.09.020","article-title":"Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5","volume":"157","author":"Chia","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2025.100960_bib21","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","article-title":"Two-year clinical trial of the Low-Concentration Atropine for Myopia Progression (LAMP) study: phase 2 report","volume":"127","author":"Yam","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100960_bib22","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","article-title":"Three-year clinical trial of Low-Concentration Atropine for Myopia Progression (LAMP) study: continued versus washout: phase 3 report","volume":"129","author":"Yam","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100960_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1167\/iovs.66.12.39","article-title":"IMI-interventions for controlling myopia onset and progression 2025","volume":"66","author":"Bullimore","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100960_bib24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/APO.0000000000000609","article-title":"Atropine ophthalmic solution to reduce myopia progression in pediatric subjects: the randomized, double-blind multicenter phase II APPLE study","volume":"12","author":"Chia","year":"2023","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.xops.2025.100960_bib25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/ICL.0000000000000990","article-title":"Compounded 0.01% atropine\u2014what\u2019s in the bottle?","volume":"49","author":"Richdale","year":"2023","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.xops.2025.100960_bib26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10384-021-00822-y","article-title":"Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study","volume":"65","author":"Hieda","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.xops.2025.100960_bib27","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jamaophthalmol.2023.2097","article-title":"Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial","volume":"141","author":"Zadnik","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2025.100960_bib28","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1111\/aos.15761","article-title":"Myopia outcome study of atropine in children: two-year result of daily 0.01% atropine in a European population","volume":"102","author":"Loughman","year":"2024","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.xops.2025.100960_bib29","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s10384-023-01012-8","article-title":"Assessment of myopic rebound effect after discontinuation of treatment with 0.01% atropine eye drops in Japanese school-age children","volume":"67","author":"Hieda","year":"2023","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.xops.2025.100960_bib30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/opo.13403","article-title":"Efficacy in myopia control\u2014the impact of rebound","volume":"45","author":"Bullimore","year":"2025","journal-title":"Ophthalmic Physiol Opt"},{"key":"10.1016\/j.xops.2025.100960_bib31","article-title":"Interventions for myopia control in children: a living systematic review and network meta-analysis","volume":"2","author":"Lawrenson","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.xops.2025.100960_bib32","first-page":"671","article-title":"An explanation for the long duration of mydriatic effect of atropine in eye","volume":"15","author":"Salazar","year":"1976","journal-title":"Invest Ophthalmol"},{"key":"10.1016\/j.xops.2025.100960_bib33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41433-021-01668-x","article-title":"Ocular benzalkonium chloride exposure: problems and solutions","volume":"36","author":"Goldstein","year":"2022","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xops.2025.100960_bib34","first-page":"1535","article-title":"Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression","volume":"104","author":"Fu","year":"2020","journal-title":"Br J Ophthalmol"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914525002581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914525002581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:55:43Z","timestamp":1773316543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914525002581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2666914525002581"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2025.100960","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Low-Concentration Atropine in Slowing Myopia Progression in Children in Japan: The Randomized, Double-Blind Phase II\/III ORANGE Study","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2025.100960","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100960"}}